Targets › SN38
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on SN38, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Valent Technologies | VAL-413 (Orotecan®) Topoisomerase I inhibitor | SN38 | Phase 1 | Solid Tumors | Dec 2026 |
Solid Tumors (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.